BRPI0820802A2 - Materiais e métodos para tratamento de proliferação vascular ocular patológica - Google Patents

Materiais e métodos para tratamento de proliferação vascular ocular patológica

Info

Publication number
BRPI0820802A2
BRPI0820802A2 BRPI0820802-6A BRPI0820802A BRPI0820802A2 BR PI0820802 A2 BRPI0820802 A2 BR PI0820802A2 BR PI0820802 A BRPI0820802 A BR PI0820802A BR PI0820802 A2 BRPI0820802 A2 BR PI0820802A2
Authority
BR
Brazil
Prior art keywords
materials
methods
vascular proliferation
treating pathological
ocular vascular
Prior art date
Application number
BRPI0820802-6A
Other languages
English (en)
Inventor
Josef Neu
Maria B Grant
Joshua Anthony
Kristin Morris
Eduard Poels
Deborah Schade
Hugh Tucker
Original Assignee
Univ Florida
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida, Bristol Myers Squibb Co filed Critical Univ Florida
Publication of BRPI0820802A2 publication Critical patent/BRPI0820802A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0820802-6A 2007-12-17 2008-12-17 Materiais e métodos para tratamento de proliferação vascular ocular patológica BRPI0820802A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1418007P 2007-12-17 2007-12-17
PCT/US2008/087125 WO2009079544A1 (en) 2007-12-17 2008-12-17 Materials and methods for treatment of pathological ocular vascular proliferation

Publications (1)

Publication Number Publication Date
BRPI0820802A2 true BRPI0820802A2 (pt) 2015-06-16

Family

ID=40411080

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820802-6A BRPI0820802A2 (pt) 2007-12-17 2008-12-17 Materiais e métodos para tratamento de proliferação vascular ocular patológica

Country Status (8)

Country Link
US (1) US20090192226A1 (pt)
EP (1) EP2219639A1 (pt)
CN (1) CN101939000A (pt)
BR (1) BRPI0820802A2 (pt)
CA (1) CA2709579A1 (pt)
MX (1) MX2010006650A (pt)
RU (1) RU2010129825A (pt)
WO (1) WO2009079544A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120121562A1 (en) * 2009-07-31 2012-05-17 Nestec S.A. Nutritional composition for breast-fed infants or pets with probiotics and selected nutrients
DK2289527T3 (en) 2009-08-25 2018-04-23 Nestec Sa BIFIDOBACTERIUM LONGUM AND FUNCTIONAL GI DISEASES
US20110208153A1 (en) * 2010-02-24 2011-08-25 John Alvey Formulations and methods for nutrient delivery
CA2825022A1 (en) 2011-01-25 2012-08-02 Nestec S.A. Methods and compositions for treating, reducing, or preventing deterioration of the visual system of animals
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
CN103948581B (zh) * 2014-02-26 2018-05-08 青岛大学医学院附属医院 左卡尼汀联合l-精氨酸在制备治疗糖尿病视网膜病变神经损伤药物中的应用
DE102015101273A1 (de) 2015-01-29 2016-08-04 Eberhard Karls Universität Tübingen Medizinische Fakultät Prophylaxe und Behandlung von frühgeburtlichkeitsassoziierten Entwicklungsstörungen
CN109010264A (zh) * 2018-08-18 2018-12-18 河北科技大学 一种ω-3脂肪酸或ω-3脂肪酸酯制剂及其新用途
WO2020240558A1 (en) * 2019-05-28 2020-12-03 Elgan Pharma Ltd Compositions and methods for treating retinopathy
EP4442269A1 (en) * 2021-12-01 2024-10-09 Seinda Pharmaceutical Guangzhou Corporation Novel use of alanyl-glutamine and ophthalmic composition comprising alanyl-glutamine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU209973B (en) * 1988-03-09 1995-01-30 Biorex Kutato Fejlesztoe Kft Process for production of antiviral and immunstimular pharmaceutical composition
RU2177801C1 (ru) * 2001-01-25 2002-01-10 Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" Средство, ингибирующее ангиогенез при заболеваниях органа зрения
WO2003017787A1 (en) * 2001-08-23 2003-03-06 University Of Florida Dipeptides for prevention of muscle breakdown and microbial infection
US20040001817A1 (en) * 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
US20050089547A1 (en) * 2003-09-26 2005-04-28 Josef Neu Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation
US7887847B2 (en) * 2004-05-08 2011-02-15 Paul Jr Edward L Nutritional supplement for treatment of ocular diseases
ATE510464T1 (de) * 2005-08-26 2011-06-15 Nestec Sa ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERBESSERUNG DER FUNKTIONALEN GEFÄßINTEGRITÄT, DES ÜBERLEBENS DER ZELLEN UND DER REDUCTION DER APOPTOSE NACH EINEM ISCHÄMIEANFALL IM GEHIRN
US20070166354A1 (en) * 2005-10-26 2007-07-19 Bridget Barrett-Reis Method of reducing the risk of retinopathy of prematurity in preterm infants
US20100048705A1 (en) * 2006-11-09 2010-02-25 Children's Medical Center Corporation Methods of treating and preventing neovascularization with omega-3 polyunsaturated fatty acids

Also Published As

Publication number Publication date
CA2709579A1 (en) 2009-06-25
MX2010006650A (es) 2010-09-28
RU2010129825A (ru) 2012-01-27
WO2009079544A1 (en) 2009-06-25
US20090192226A1 (en) 2009-07-30
CN101939000A (zh) 2011-01-05
EP2219639A1 (en) 2010-08-25

Similar Documents

Publication Publication Date Title
BRPI0820802A2 (pt) Materiais e métodos para tratamento de proliferação vascular ocular patológica
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
PT2367561E (pt) Composições e métodos para o tratamento da doença celíaca
BRPI0807918A2 (pt) composições e método para preservação de tecido
BRPI0911923A2 (pt) dispositivos filamentosos para o tratamento de defeitos vasculares
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
BRPI0813212A2 (pt) Métodos de tratamento de doenças e distúrbios mediados por serotonina
BRPI0810206A2 (pt) Método de tratar câncer
PT1881823E (pt) Composições e métodos para o tratamento de transtornos oculares
BRPI0911757A2 (pt) composiÇÕes e mÉtodos para tratar distérbios digestivos.
BRPI0919920A2 (pt) compostos para tratamento de doenças e desordens oftálmicas
BRPI0812767A2 (pt) Anticorpos para c3b e métodos para prevenção e tratamento de distúrbios associados ao complemento
BRPI1006145A2 (pt) "composição e método para tratamento de diabetes".
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BRPI0919804A2 (pt) Métodos e composição para o tratemento de problemas dermatológicos e/ou condições de cabelo
BRPI0822349A2 (pt) composições e métodos para tratar doenças lisossômicas
BRPI0813670A2 (pt) Compostos para tratamento
BRPI0820477A2 (pt) Compostos de benzodiazepinona úteis no tratamento de afecções da pele
BRPI0911083A2 (pt) métodos para o tratamento ou prenvenção de diabetes mullitus e outros desequilíbrios metabólicos
BRPI0810946A2 (pt) Método para tratamento de hérnia de disco
BRPI1007929A2 (pt) "métodos e composições para o tratamento de neovascularização".
BRPI0922884A2 (pt) compostos para tratamento de câncer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.